Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Internationally renowned ophthalmologist, Gerd Auffarth, MD, ranked as one of the “100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist magazine Julian Gangolli, former President of the North American Pharmaceutical division of Allergan, Inc., brings distinguished track record of successfully overseeing product commercialization launches CRANBURY, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage?biopharmaceutical company?working to develop the first FDA-approved ophthalmic formulation of bevacizumab?for use in retinal?indications, today announced it has bolstered its Board of Directors with the appointments of Prof. Dr. Gerd Auffarth and Mr. Julian Gangolli. “We are incredibly pleased to add individuals of Dr. Auffarth’s and Mr. Gangolli’s caliber to the Outlook Therapeutics Board of Directors,” stated Lawrence A. Kenyon, President, CEO and CF
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMDGlobeNewswire
- Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010GlobeNewswire
OTLK
Earnings
- 8/14/25 - Miss
OTLK
Sec Filings
- 11/3/25 - Form 8-K
- 10/21/25 - Form SCHEDULE
- 10/3/25 - Form 4
- OTLK's page on the SEC website